Infant nutrition with protease inhibitor

Abstract

Provided is an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of childhood obesity and secondary disorders resulting from childhood obesity.

1 . A method of providing nutrition to an infant comprising administering to the infant a composition comprising:
 (a) 5 to 16 en. % protein;   (b) 35 to 60 en. % fat, wherein at least one fat is selected from the group consisting of vegetable fat, marine fat and microbial fat;   (c) 25 to 75 en. % carbohydrate; and   (d) a protease inhibitor selected from the group consisting of trypsin inhibitors, chymotrypsin inhibitors, and elastase inhibitors.   
     
     
         2 . The method according to  claim 1 , wherein the composition comprises a vegetable fat. 
     
     
         3 . The method according to  claim 1 , wherein the protease inhibitor is obtained from potato, leguminous seeds, non-human milk, avian egg white, microbial culture, or combinations thereof. 
     
     
         4 . The method according to  claim 1 , wherein the protease inhibitor is α1-antitrypsin, α1-proteinase inhibitor, α1-antichymotrypsin, bovine Kunitz trypsin inhibitor, trypsin-chymotrypsin inhibitor, Bowman-Birk inhibitor, trypsin inhibitor, type II-O, ovoinhibitor, serpin, potato inhibitor I, potato inhibitor II, or zinc gluconate. 
     
     
         5 . The method according to  claim 4 , wherein (a) α1-antitrypsin, α1-proteinase inhibitor, and/or α1-antichymotrypsin is obtained from human plasma; (b) bovine Kunitz trypsin inhibitor is obtained from colostrum; (c) trypsin-chymotrypsin inhibitor and/or Bowman-Birk inhibitor is obtained from soy bean; (d) trypsin inhibitor, type II-O, and/or ovoinhibitor is obtained from chicken egg white; and/or (e) serpin is obtained from  Bifidobacteria.    
     
     
         6 . The method according to  claim 1 , wherein the composition comprises 35 μg to 14 mg protease inhibitor per gram of dry weight of the composition. 
     
     
         7 . The method according to  claim 1 , wherein the composition comprises 0.75 to 300 units of protease inhibitor per g dry weight of the composition, wherein one protease inhibitor unit is the activity that inhibits one unit of the activity of the sum of trypsin activity, chymotrypsin activity and elastase activity. 
     
     
         8 . The method according to  claim 1 , wherein the protease inhibitor is present from 20 to 5000% of the protease inhibitor activity as obtained by 1.1 mg human serum α1-antitrypsin and 0.18 mg human serum α1-antichymotrypsin per g dry weight of the composition. 
     
     
         9 . The method according to  claim 1 , wherein a portion of the carbohydrate in the composition is digestible carbohydrate. 
     
     
         10 . The method according to  claim 9 , wherein at least 50 wt. % of the digestible carbohydrate comprises lactose. 
     
     
         11 . The method according to  claim 1 , wherein the composition further comprises 1-10 wt. % non-digestible, fermentable carbohydrates selected from the group consisting of trans-galacto-oligosaccharides, inulin, fructo-oligosaccharides, galacturonic acid oligosaccharides, partially hydrolysed guar gum and indigestible polydextrose, based on dry weight of the composition. 
     
     
         12 . The method according to  claim 1 , wherein the composition is an infant formula or follow-on formula. 
     
     
         13 . A method of treating a child suffering from childhood obesity or at increased risk of developing childhood obesity, comprising administering to the child in need thereof a composition comprising:
 (a) 5 to 16 en. % protein;   (b) 35 to 60 en. % fat, wherein at least one fat is selected from the group consisting of vegetable fat, marine fat and microbial fat;   (c) 25 to 75 en. % carbohydrate; and   (d) a protease inhibitor selected from the group consisting of trypsin inhibitors, chymotrypsin inhibitors, and elastase inhibitors.   
     
     
         14 . The method according to  claim 13 , wherein the protease inhibitor is α1-antitrypsin or α1-proteinase inhibitor, from human plasma; α1-antichymotrypsin from human plasma; bovine Kunitz trypsin inhibitor from colostrum; trypsin-chymotrypsin inhibitor or Bowman-Birk inhibitor, from soy bean; trypsin inhibitor, type II-O, or ovoinhibitor, from chicken egg white; serpin from  Bifidobacteria ; potato inhibitor I; potato inhibitor II; zinc gluconate. 
     
     
         15 . The method according to  claim 13 , wherein the composition comprises 35 μg to 14 mg protease inhibitor per gram of dry weight of the composition. 
     
     
         16 . The method according to  claim 13 , wherein the composition comprises 0.75 to 300 units of protease inhibitor per g dry weight of the composition, wherein one protease inhibitor unit is the activity that inhibits one unit of the activity of the sum of trypsin activity, chymotrypsin activity and elastase activity. 
     
     
         17 . The method according to  claim 13 , wherein the composition further comprises 1-10 wt. % non-digestible, fermentable carbohydrates selected from the group consisting of trans-galacto-oligosaccharides, inulin, fructo-oligosaccharides, galacturonic acid oligosaccharides, partially hydrolysed guar gum and indigestible polydextrose, based on dry weight of the composition. 
     
     
         18 . A method for the treatment and/or prevention of diabetes, cardiovascular diseases, hypertension, asthma, sleep apnoea, orthopaedic disorders and/or arthritis in a child suffering from childhood obesity, said method comprising orally administering to the child a composition comprising:
 (a) 5 to 16 en. % protein;   (b) 35 to 60 en. % fat, wherein at least one fat is selected from the group consisting of vegetable fat, marine fat and microbial fat;   (c) 25 to 75 en. % carbohydrate; and   (d) a protease inhibitor selected from the group consisting of trypsin inhibitors, chymotrypsin inhibitors, and elastase inhibitors.   
     
     
         19 . The method according to  claim 18 , wherein the composition comprises 35 μg to 14 mg protease inhibitor per gram of dry weight of the composition. 
     
     
         20 . The method according to  claim 18 , wherein the composition further comprises 1-10 wt. % non-digestible, fermentable carbohydrates selected from the group consisting of trans-galacto-oligosaccharides, inulin, fructo-oligosaccharides, galacturonic acid oligosaccharides, partially hydrolysed guar gum and indigestible polydextrose, based on dry weight of the composition.